David Horrobin Bibliography
2001
860
Ewin, J.H. and Horrobin, D.F.
Fine wines and fish oil: the life of Hugh MacDonald Sinclair
Oxford University Press, 362pp 2001.
(Abstract)


861
Horrobin, D.F.
The paradox of antioxidants and cancer [letter]
Am J Clin Pract 2001; 74(4): 555-6.
(Full text)  

862
Horrobin, D.F.
The madness of Adam and Eve. How schizophrenia shaped humanity.
Bantam, London. 275 pp 2001.
(Abstract)


863
Horrobin, D.F.
More on burns after photodynamic therapy. Might doctors performing the study have been given the wrong injection instructions? [letter]
Br Med J 2001; 322(7279): 171-2.
(Full text)  

864
Horrobin, D.F.
New drug discovery techniques are not so revolutionary [letter]
Br Med J 2001; 322(7280): 239.
(Full text)  

865
Horrobin, D.F.
Burns After Photodynamic Therapy [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/322/7279/171/a#12498 2001.
(Full text)  

866
Horrobin, D.F.
Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase
Hum Psychopharmacol 2001; 16(1): 45-52.
(Abstract)


867
Horrobin, D.F.
Disorders of phospholipid metabolism in schizophrenia, affective disorders and neurodegenerative disorders
In: Fatty Acids: Physiological and Behavioural Functions. Mostofsky, D.I., Yehuda, S. and Salem, N. (Eds.), Humana Press, Totawa, NJ 2001: 331-4.


868
Horrobin, D.F.
Gamma-linolenic acid in diabetes
In: Huang, Y.S.; Ziboh, V.A. (Eds.) Gamma-linolenic acid: recent advances in biotechnology and clinical applications. American Oil Chemists Society, Champaign, Illinois. 2001: 105-11.
(Abstract)


869
Horrobin, D.F.
[Foreward]
In: Yabrov, A.A.; Slonim, M.A. How man exists. 1stBooks Library, Indiana. 2001: V.


870
Horrobin, D.F.
Realism in drug discovery - could Cassandra be right?
Nature Biotechnol 2001; 19(12): 1099-100.


871
Horrobin, D.F.
Something rotten at the core of science?
Trends Pharmacol Sci 2001; 22(2): 51-2.
(Full text)  (Abstract)


872
Horrobin, D.F.; Bennett, C.N.; Peet, M.
Correlation between clinical improvement and red cell fatty acid changes when treating schizophrenia with eicosapentaenoic acid
Schizophr Res 2001; 49: 232.


873
Horrobin, D.F. and Peet, M.
Ethyl-eicosapentaenoate (LAX-101) in treatment-unresponsive depression (Abstract)
Bipolar Disorders 2001; 3: 42.


874
Horrobin, D.F. and Peet, M.A.
A dose-ranging study of ethyl-eicosapentaenoate in treatment-unresponsive depression (Abstract)
Biol Psychiatry 2001; 49: 37S.


875
Peet, M. and Horrobin, D.F.
The role of phospholipids in schizophrenia (Abstract)
Presented at: Society of Biological Psychiatry Annual Meeting 2001.


876
Puri, B.K.; Bydder, G.M.; Chaudhuri, K.R.; Al Saffar, B.Y.; Curati, W.L.; White, S.J.; Mitchell, L.; Hajnal, J.V.; Horrobin, D.F.
MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine
Neuroreport 2001; 12(9): 1821-4.
(Abstract)


877
Puri, B.K.; Counsell, S.J.; Hamilton, G.; Richardson, A.J.; Horrobin, D.F.
Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover
Int J Clin Pract 2001; 55(8): 560-3.
(Abstract)


878
Puri, B.K. and Horrobin, D.F.
Decrease in cerebral ventricular volume in end-stage Huntington's disease treated with puri.ed eicosapentaenoic acid (Poster)
Presented at: International Society for Magnetic Resonance in Medicine Meeting, Glasgow, UK, April 2001.




All copyrights acknowledged

© Peter Lapinskas 1999-2012 Email Peter Lapinskas Last updated: 3 July 2012

Home      Services      Background      Publications      Resources      Contact